BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 28332225)

  • 1. Molecular Dynamics Validation of Crizotinib Resistance to ALK Mutations (L1196M and G1269A) and Identification of Specific Inhibitors.
    Nagasundaram N; Wilson Alphonse CR; Samuel Gnana PV; Rajaretinam RK
    J Cell Biochem; 2017 Oct; 118(10):3462-3471. PubMed ID: 28332225
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer.
    Friboulet L; Li N; Katayama R; Lee CC; Gainor JF; Crystal AS; Michellys PY; Awad MM; Yanagitani N; Kim S; Pferdekamper AC; Li J; Kasibhatla S; Sun F; Sun X; Hua S; McNamara P; Mahmood S; Lockerman EL; Fujita N; Nishio M; Harris JL; Shaw AT; Engelman JA
    Cancer Discov; 2014 Jun; 4(6):662-673. PubMed ID: 24675041
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Computationally unraveling how ceritinib overcomes drug-resistance mutations in ALK-rearranged lung cancer.
    Ni Z; Zhang TC
    J Mol Model; 2015 Jul; 21(7):175. PubMed ID: 26084268
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activity of second-generation ALK inhibitors against crizotinib-resistant mutants in an NPM-ALK model compared to EML4-ALK.
    Fontana D; Ceccon M; Gambacorti-Passerini C; Mologni L
    Cancer Med; 2015 Jul; 4(7):953-65. PubMed ID: 25727400
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multiplexed deep sequencing analysis of ALK kinase domain identifies resistance mutations in relapsed patients following crizotinib treatment.
    Huang D; Kim DW; Kotsakis A; Deng S; Lira P; Ho SN; Lee NV; Vizcarra P; Cao JQ; Christensen JG; Kim TM; Sun JM; Ahn JS; Ahn MJ; Park K; Mao M
    Genomics; 2013 Sep; 102(3):157-62. PubMed ID: 23434628
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Detection of ALK and KRAS Mutations in Circulating Tumor DNA of Patients With Advanced ALK-Positive NSCLC With Disease Progression During Crizotinib Treatment.
    Bordi P; Tiseo M; Rofi E; Petrini I; Restante G; Danesi R; Del Re M
    Clin Lung Cancer; 2017 Nov; 18(6):692-697. PubMed ID: 28601386
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anaplastic Lymphoma Kinase (ALK) Kinase Domain Mutation Following ALK Inhibitor(s) Failure in Advanced ALK Positive Non-Small-Cell Lung Cancer: Analysis and Literature Review.
    Lin YT; Yu CJ; Yang JC; Shih JY
    Clin Lung Cancer; 2016 Sep; 17(5):e77-e94. PubMed ID: 27130468
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Overcoming crizotinib resistance in ALK-rearranged NSCLC with the second-generation ALK-inhibitor ceritinib.
    Muller IB; De Langen AJ; Honeywell RJ; Giovannetti E; Peters GJ
    Expert Rev Anticancer Ther; 2016; 16(2):147-57. PubMed ID: 26654422
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Heterogeneity of genetic changes associated with acquired crizotinib resistance in ALK-rearranged lung cancer.
    Kim S; Kim TM; Kim DW; Go H; Keam B; Lee SH; Ku JL; Chung DH; Heo DS
    J Thorac Oncol; 2013 Apr; 8(4):415-22. PubMed ID: 23344087
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antitumor activity of alectinib, a selective ALK inhibitor, in an ALK-positive NSCLC cell line harboring G1269A mutation: Efficacy of alectinib against ALK G1269A mutated cells.
    Yoshimura Y; Kurasawa M; Yorozu K; Puig O; Bordogna W; Harada N
    Cancer Chemother Pharmacol; 2016 Mar; 77(3):623-8. PubMed ID: 26849637
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ALK inhibitors: what is the best way to treat patients with ALK+ non-small-cell lung cancer?
    Toyokawa G; Seto T
    Clin Lung Cancer; 2014 Sep; 15(5):313-9. PubMed ID: 24984564
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Precision medicine against ALK-positive non-small cell lung cancer: beyond crizotinib.
    Ricciuti B; De Giglio A; Mecca C; Arcuri C; Marini S; Metro G; Baglivo S; Sidoni A; Bellezza G; Crinò L; Chiari R
    Med Oncol; 2018 Apr; 35(5):72. PubMed ID: 29666949
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Computational Investigation and Experimental Validation of Crizotinib Resistance Conferred by C1156Y Mutant Anaplastic Lymphoma Kinase.
    Kumar A; Shanthi V; Ramanathan K
    Mol Inform; 2015 Feb; 34(2-3):105-14. PubMed ID: 27490033
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel acquired ALK F1245C mutation confers resistance to crizotinib in ALK-positive NSCLC but is sensitive to ceritinib.
    Kodityal S; Elvin JA; Squillace R; Agarwal N; Miller VA; Ali SM; Klempner SJ; Ou SH
    Lung Cancer; 2016 Feb; 92():19-21. PubMed ID: 26775591
    [TBL] [Abstract][Full Text] [Related]  

  • 15. P-glycoprotein Mediates Ceritinib Resistance in Anaplastic Lymphoma Kinase-rearranged Non-small Cell Lung Cancer.
    Katayama R; Sakashita T; Yanagitani N; Ninomiya H; Horiike A; Friboulet L; Gainor JF; Motoi N; Dobashi A; Sakata S; Tambo Y; Kitazono S; Sato S; Koike S; John Iafrate A; Mino-Kenudson M; Ishikawa Y; Shaw AT; Engelman JA; Takeuchi K; Nishio M; Fujita N
    EBioMedicine; 2016 Jan; 3():54-66. PubMed ID: 26870817
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An interaction map of small-molecule kinase inhibitors with anaplastic lymphoma kinase (ALK) mutants in ALK-positive non-small cell lung cancer.
    Ai X; Shen S; Shen L; Lu S
    Biochimie; 2015 May; 112():111-20. PubMed ID: 25769414
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of a novel T1151K ALK mutation in a patient with ALK-rearranged NSCLC with prior exposure to crizotinib and ceritinib.
    Zhu VW; Cui JJ; Fernandez-Rocha M; Schrock AB; Ali SM; Ou SI
    Lung Cancer; 2017 Aug; 110():32-34. PubMed ID: 28676215
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anaplastic lymphoma kinase inhibitors in phase I and phase II clinical trials for non-small cell lung cancer.
    Karachaliou N; Santarpia M; Gonzalez Cao M; Teixido C; Sosa AE; Berenguer J; Rodriguez Capote A; Altavilla G; Rosell R
    Expert Opin Investig Drugs; 2017 Jun; 26(6):713-722. PubMed ID: 28463570
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Crizotinib-Resistant ROS1 Mutations Reveal a Predictive Kinase Inhibitor Sensitivity Model for ROS1- and ALK-Rearranged Lung Cancers.
    Facchinetti F; Loriot Y; Kuo MS; Mahjoubi L; Lacroix L; Planchard D; Besse B; Farace F; Auger N; Remon J; Scoazec JY; André F; Soria JC; Friboulet L
    Clin Cancer Res; 2016 Dec; 22(24):5983-5991. PubMed ID: 27401242
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Next-generation sequencing reveals a Novel NSCLC ALK F1174V mutation and confirms ALK G1202R mutation confers high-level resistance to alectinib (CH5424802/RO5424802) in ALK-rearranged NSCLC patients who progressed on crizotinib.
    Ignatius Ou SH; Azada M; Hsiang DJ; Herman JM; Kain TS; Siwak-Tapp C; Casey C; He J; Ali SM; Klempner SJ; Miller VA
    J Thorac Oncol; 2014 Apr; 9(4):549-53. PubMed ID: 24736079
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.